Announcements Trials
Browse Landscape

Phase

Phase 1 25Phase 1/2 19Phase 3 6Phase 2 4Phase 4 2Phase 2/3 1

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 19INDUSTRY 4NIH 3

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Arthritis, Rheumatoid 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × tocilizumab × Clear all
NCT05207670 2026-06-03

MorningSun

Genentech, Inc.

Phase 2 Active not recruiting
320 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT07589634 2026-05-15

TRI Pro

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
230 enrolled
Plasma cell

Multiple Myeloma

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Lymphoma

NCT01242488 2024-07-17

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
221 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡